image credit- shutterstock
Morepen Laboratories, one of India’s leading pharmaceutical companies, has announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country.
As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone.
Following consistently encouraging growth in the segment, this move marks a significant step in strengthening Morepen’s formulations business in the market, reinforcing its commitment to building a stronger domestic footprint and aligning with India’s vision of affordable, accessible healthcare for all.
Currently, Morepen’s formulation business stands at approximately Rs 325 crore, and the company is targeting a Rs 1,000 crore finished dosages business within the next five years. This goal will be supported by an aggressive expansion of its medical representative network and deeper market penetration across urban and rural India, with major growth expected from new products that the company is already producing at highly competitive costs.
Morepen’s expansion builds on its strong legacy as India’s leading APIs exporter for six leading products including Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine.
